Want to look younger but don’t want to prod your face with injections? You’re not alone because it turns out plenty of youth seekers are consuming collagen via less invasive beauty techniques with Eve Health (ASX: EVE) reporting strong sales of their probiotic concentrate drinks, including those infused with collagen.
Such demand has seen Eve subsidiary Meluka Australia generate $750k in sales for the 6 months ended 31 December 2022. This represented a 34% increase to the previous corresponding period as Australians opened their wallets to health and wellness products over the holiday season.
The main driver behind the jump in revenue came from Meluka’s probiotic beverage range which are marketed to contain concentrated honey probiotics.
“Meluka Australia has had an impressive six-month period, with growth across Australia, North America and Japan,” said Meluka Australia CEO, Ben Rohr.
“Distribution and expansion plans are well progressed with new products expected to expand our brand awareness and grow sales accordingly.”
Given the impressive results over the past six months, Meluka has confirmed its ambitious plans to expand its range of Collagen Probiotic Concentrate drinks with the first product launched last month. This would see a further four collagen drinks launched before the end of March 2022.
Collagen is best known in beauty circles as a product that can be injected into the skin to maintain elasticity and firming as an anti-aging procedure.
Demand for such products has long come from Asian markets which Meluka is actively targeting. With such audiences primarily active on direct messaging channels, Meluka is set to launch a new eCommerce store on WhatsApp Commerce shortly,
Australia’s data-centre construction sector continues to surge on the back of cloud adoption, AI-driven computing…
A major Australian research initiative is set to push forward global understanding of brain injury,…
Following a successful FY25 which saw a boost in gross profit after launching its refurbished…
Pivotal Metals (ASX:PVT) has locked in $5.4 million in fresh funding to accelerate exploration across…
Biotech company Biotron Limited (ASX:BIT) has announced a bold step into the anaesthetics sector, acquiring…
DroneShield (ASX:DRO) is expanding its Australian footprint with a $13 million investment to establish a…